KR101850661B1 - 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 - Google Patents
트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 Download PDFInfo
- Publication number
- KR101850661B1 KR101850661B1 KR1020177003353A KR20177003353A KR101850661B1 KR 101850661 B1 KR101850661 B1 KR 101850661B1 KR 1020177003353 A KR1020177003353 A KR 1020177003353A KR 20177003353 A KR20177003353 A KR 20177003353A KR 101850661 B1 KR101850661 B1 KR 101850661B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- compound
- compound represented
- optionally substituted
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1=N*2C=CC=CC2N1 Chemical compound CC1=N*2C=CC=CC2N1 0.000 description 2
- KRHPHZSDBGDRIU-UHFFFAOYSA-N Ic1n[n](cccc2)c2n1 Chemical compound Ic1n[n](cccc2)c2n1 KRHPHZSDBGDRIU-UHFFFAOYSA-N 0.000 description 2
- ODNMSQWNSQJUIJ-UHFFFAOYSA-O CBCCCCCC(N1)=CC(OC)=C(C(O)=O)/C1=N/C=[NH2+] Chemical compound CBCCCCCC(N1)=CC(OC)=C(C(O)=O)/C1=N/C=[NH2+] ODNMSQWNSQJUIJ-UHFFFAOYSA-O 0.000 description 1
- XIJLTNFJISTDKC-UHFFFAOYSA-N CC(C)(C)OC(C(C(C(Br)=CN1Cc2ccccc2)=O)=C1Cl)=O Chemical compound CC(C)(C)OC(C(C(C(Br)=CN1Cc2ccccc2)=O)=C1Cl)=O XIJLTNFJISTDKC-UHFFFAOYSA-N 0.000 description 1
- QWBJTBLQWKQPRT-UHFFFAOYSA-N CC(C)(C)OC(c(c(O)c(cn1)Br)c1Cl)=O Chemical compound CC(C)(C)OC(c(c(O)c(cn1)Br)c1Cl)=O QWBJTBLQWKQPRT-UHFFFAOYSA-N 0.000 description 1
- HLGCOFLWTBFGCI-UHFFFAOYSA-N CC(C)(C)OC(c(c(OCc1ccccc1)ccn1)c1Cl)=O Chemical compound CC(C)(C)OC(c(c(OCc1ccccc1)ccn1)c1Cl)=O HLGCOFLWTBFGCI-UHFFFAOYSA-N 0.000 description 1
- PPBOXOGFHCGKSW-UHFFFAOYSA-N CC(C)(C)OC(c(c1ncn[n]1c(I)c1)c1OCc1ccccc1)=O Chemical compound CC(C)(C)OC(c(c1ncn[n]1c(I)c1)c1OCc1ccccc1)=O PPBOXOGFHCGKSW-UHFFFAOYSA-N 0.000 description 1
- PIZBOTSMGZRWCL-UHFFFAOYSA-N CC(C)(C)OC(c(c1ncn[n]1cc1)c1OCc1ccccc1)=O Chemical compound CC(C)(C)OC(c(c1ncn[n]1cc1)c1OCc1ccccc1)=O PIZBOTSMGZRWCL-UHFFFAOYSA-N 0.000 description 1
- YWIROZLWHOKVHD-UHFFFAOYSA-N CC(C)(C)OC(c1c(NN)nccc1OCc1ccccc1)=O Chemical compound CC(C)(C)OC(c1c(NN)nccc1OCc1ccccc1)=O YWIROZLWHOKVHD-UHFFFAOYSA-N 0.000 description 1
- KDXOIDIMSIJKCQ-UHFFFAOYSA-N CCC(CC)c1cc(O)c(C(NCC(O)=O)=O)c2ncn[n]12 Chemical compound CCC(CC)c1cc(O)c(C(NCC(O)=O)=O)c2ncn[n]12 KDXOIDIMSIJKCQ-UHFFFAOYSA-N 0.000 description 1
- HVNJRDMHSCCLQP-UHFFFAOYSA-O CCCCC(N1)=CC(Cl)=C(C(OC)=O)/C1=N/C=[NH2+] Chemical compound CCCCC(N1)=CC(Cl)=C(C(OC)=O)/C1=N/C=[NH2+] HVNJRDMHSCCLQP-UHFFFAOYSA-O 0.000 description 1
- CESZWQPHGRZIGB-UHFFFAOYSA-N CCCCC(N1)=CC(O)=C(C(NCC(O)=O)=O)/C1=N/C=N Chemical compound CCCCC(N1)=CC(O)=C(C(NCC(O)=O)=O)/C1=N/C=N CESZWQPHGRZIGB-UHFFFAOYSA-N 0.000 description 1
- CBQNGNWCCMQAKA-UHFFFAOYSA-N CCCCC(N1)=CC(OC)=C(C(NCC(OC(C)(C)C)=O)=O)/C1=[N-]/C=N Chemical compound CCCCC(N1)=CC(OC)=C(C(NCC(OC(C)(C)C)=O)=O)/C1=[N-]/C=N CBQNGNWCCMQAKA-UHFFFAOYSA-N 0.000 description 1
- KKAFSNZTOBHLNF-UHFFFAOYSA-O COC(C(/C(/NC(CCc1ccccc1)=C1)=N/C=[NH2+])=C1Cl)=O Chemical compound COC(C(/C(/NC(CCc1ccccc1)=C1)=N/C=[NH2+])=C1Cl)=O KKAFSNZTOBHLNF-UHFFFAOYSA-O 0.000 description 1
- PBNZOYHERXPDIW-UHFFFAOYSA-N COC(C(/C(/NC(Cl)=C1)=N/C=N)=C1Cl)=O Chemical compound COC(C(/C(/NC(Cl)=C1)=N/C=N)=C1Cl)=O PBNZOYHERXPDIW-UHFFFAOYSA-N 0.000 description 1
- VTJBXTYHYNUSTC-UHFFFAOYSA-N COC(CNC(c([n]1nncc1cc1)c1O)=O)=O Chemical compound COC(CNC(c([n]1nncc1cc1)c1O)=O)=O VTJBXTYHYNUSTC-UHFFFAOYSA-N 0.000 description 1
- ZKRCQSJMYWLQJB-UHFFFAOYSA-N COC(CNC(c([n]1nncc1cc1)c1OCc1ccccc1)=O)=O Chemical compound COC(CNC(c([n]1nncc1cc1)c1OCc1ccccc1)=O)=O ZKRCQSJMYWLQJB-UHFFFAOYSA-N 0.000 description 1
- XSZKVKMGSAAAJZ-UHFFFAOYSA-N Cc1c(C(O)=O)c(C)ncc1 Chemical compound Cc1c(C(O)=O)c(C)ncc1 XSZKVKMGSAAAJZ-UHFFFAOYSA-N 0.000 description 1
- SYQWYIBSNAEHEZ-UHFFFAOYSA-N OC(CNC(c(c1ncn[n]1c(-c1cc(C(F)(F)F)cc(F)c1)c1)c1O)=O)=O Chemical compound OC(CNC(c(c1ncn[n]1c(-c1cc(C(F)(F)F)cc(F)c1)c1)c1O)=O)=O SYQWYIBSNAEHEZ-UHFFFAOYSA-N 0.000 description 1
- DZPRLIKYBUDOAW-UHFFFAOYSA-N OC(CNC(c(c1ncn[n]1c(-c1cc(F)cc(F)c1)c1)c1O)=O)=O Chemical compound OC(CNC(c(c1ncn[n]1c(-c1cc(F)cc(F)c1)c1)c1O)=O)=O DZPRLIKYBUDOAW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009169565 | 2009-07-17 | ||
| JPJP-P-2009-169565 | 2009-07-17 | ||
| US27312709P | 2009-07-30 | 2009-07-30 | |
| US61/273,127 | 2009-07-30 | ||
| PCT/JP2010/062037 WO2011007856A1 (ja) | 2009-07-17 | 2010-07-16 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127004258A Division KR101706803B1 (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187010331A Division KR20180042443A (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170018105A KR20170018105A (ko) | 2017-02-15 |
| KR101850661B1 true KR101850661B1 (ko) | 2018-04-19 |
Family
ID=43449466
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177003353A Active KR101850661B1 (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
| KR1020127004258A Active KR101706803B1 (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
| KR1020267000195A Pending KR20260012830A (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
| KR1020237040564A Ceased KR20230165366A (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
| KR1020187010331A Ceased KR20180042443A (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127004258A Active KR101706803B1 (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
| KR1020267000195A Pending KR20260012830A (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
| KR1020237040564A Ceased KR20230165366A (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
| KR1020187010331A Ceased KR20180042443A (ko) | 2009-07-17 | 2010-07-16 | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8283465B2 (https=) |
| EP (3) | EP3594213A1 (https=) |
| JP (9) | JP5021797B2 (https=) |
| KR (5) | KR101850661B1 (https=) |
| CN (1) | CN102471337B (https=) |
| AR (1) | AR077417A1 (https=) |
| AU (1) | AU2010271732B2 (https=) |
| BR (1) | BR112012001157A2 (https=) |
| CA (1) | CA2768505C (https=) |
| CO (1) | CO6430426A2 (https=) |
| DK (1) | DK2455381T5 (https=) |
| ES (1) | ES2477968T3 (https=) |
| HR (1) | HRP20140705T1 (https=) |
| IL (1) | IL217541A (https=) |
| ME (1) | ME01858B (https=) |
| MX (1) | MX2012000766A (https=) |
| MY (1) | MY160814A (https=) |
| NZ (1) | NZ598242A (https=) |
| PE (1) | PE20120629A1 (https=) |
| PL (1) | PL2455381T3 (https=) |
| PT (1) | PT2455381E (https=) |
| RS (1) | RS53499B1 (https=) |
| RU (1) | RU2538963C2 (https=) |
| SG (1) | SG178049A1 (https=) |
| SI (1) | SI2455381T1 (https=) |
| SM (1) | SMT201500122B (https=) |
| TW (1) | TWI485150B (https=) |
| WO (1) | WO2011007856A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3594213A1 (en) * | 2009-07-17 | 2020-01-15 | Japan Tobacco Inc. | Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers |
| JP2011168582A (ja) * | 2010-01-21 | 2011-09-01 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤 |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| CN104936591B (zh) | 2012-11-26 | 2018-05-29 | 国立大学法人东北大学 | 促红细胞生成素表达增强剂 |
| JO3781B1 (ar) | 2012-12-24 | 2021-01-31 | Cadila Healthcare Ltd | مشتقات الكينولون |
| JP2016521747A (ja) | 2013-06-13 | 2016-07-25 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 貧血治療のための組成物及び方法 |
| RU2534804C1 (ru) * | 2013-08-05 | 2014-12-10 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ |
| SG11201602572YA (en) * | 2013-10-03 | 2016-04-28 | Kura Oncology Inc | Inhibitors of erk and methods of use |
| WO2016034108A1 (zh) | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| JP2018039733A (ja) * | 2014-12-22 | 2018-03-15 | 株式会社富士薬品 | 新規複素環誘導体 |
| GB201504565D0 (en) * | 2015-03-18 | 2015-05-06 | Takeda Pharmaceutical | Novel compounds |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| EP4667059A3 (en) | 2015-05-28 | 2026-04-08 | Japan Tobacco Inc. | Method for treating or preventing diabetic nephropathy |
| KR102523786B1 (ko) * | 2016-11-25 | 2023-04-20 | 니뽄 다바코 산교 가부시키가이샤 | 트리아졸로피리딘 화합물의 제조 방법 |
| CA3062972C (en) * | 2017-05-09 | 2021-09-14 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| KR20200064101A (ko) * | 2017-10-04 | 2020-06-05 | 니뽄 다바코 산교 가부시키가이샤 | 질소 함유 헤테로아릴 화합물 및 그의 의약 용도 |
| CN107739378A (zh) * | 2017-11-14 | 2018-02-27 | 杭州安道药业有限公司 | 吲哚嗪衍生物及其在医药上的应用 |
| CA3106385A1 (en) | 2018-09-13 | 2020-03-19 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
| CN110105355B (zh) * | 2019-05-24 | 2021-09-21 | 烟台大学 | 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法 |
| KR20220152276A (ko) * | 2020-03-11 | 2022-11-15 | 깃세이 야쿠힌 고교 가부시키가이샤 | 이미다조피리디논 화합물 또는 그 염의 결정 |
| JP7504822B2 (ja) * | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物を含む医薬組成物 |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| CN113387948B (zh) * | 2021-02-06 | 2022-06-10 | 成都诺和晟泰生物科技有限公司 | 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途 |
| EP4308120A4 (en) | 2021-03-19 | 2024-11-27 | Zydus Lifesciences Limited | TREATMENT OF SICKLE CELL ANEMIA |
| EP4347022A1 (en) | 2021-05-27 | 2024-04-10 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| CN113582843A (zh) * | 2021-09-09 | 2021-11-02 | 无锡捷化医药科技有限公司 | 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法 |
| CN116496269B (zh) * | 2021-12-02 | 2025-02-28 | 苏中药业集团股份有限公司 | 一种脯氨酰羟化酶抑制剂及其用途 |
| CN114031619A (zh) * | 2021-12-17 | 2022-02-11 | 山东汇海医药化工有限公司 | 一种图卡替尼中间体的制备方法 |
| CN117327066A (zh) * | 2022-06-30 | 2024-01-02 | 上海济煜医药科技有限公司 | 一种新多晶型、其制备方法及其用于制备药物的用途 |
| JP2025529533A (ja) * | 2022-09-19 | 2025-09-04 | 蘇中薬業集団股▲ふん▼有限公司 | プロリルヒドロキシラーゼ阻害剤およびその用途 |
| TWI905781B (zh) * | 2023-06-02 | 2025-11-21 | 大陸商蘇中藥業集團股份有限公司 | 脯胺醯羥化酶抑制劑及其用途 |
| TW202506675A (zh) * | 2023-08-08 | 2025-02-16 | 美商富曼西公司 | 用於防治和對抗無脊椎有害生物的連接的雙環化合物 |
| WO2025087207A1 (zh) | 2023-10-24 | 2025-05-01 | 杭州安道药业有限公司 | 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用 |
| TW202529740A (zh) * | 2023-12-19 | 2025-08-01 | 美商阿克比治療有限公司 | Ｐｈｄ抑制劑化合物、組成物及使用方法 |
| WO2025167738A1 (zh) * | 2024-02-05 | 2025-08-14 | 深圳信立泰药业股份有限公司 | 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用 |
| CN119700755B (zh) * | 2024-02-05 | 2026-01-30 | 深圳信立泰药业股份有限公司 | 化合物在制备预防和/或治疗高原病的药物中的应用 |
| CN119039291A (zh) * | 2024-09-09 | 2024-11-29 | 南京药坦生物科技有限公司 | 一种恩那度司他中间体及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008006540A1 (en) | 2006-07-12 | 2008-01-17 | Syngenta Participations Ag | Triazolopyridine derivatives as herbicides |
| WO2009146358A1 (en) | 2008-05-29 | 2009-12-03 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine and related analogs as sirtuin modulators |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| MXPA04003277A (es) * | 2001-10-08 | 2004-07-23 | Hoffmann La Roche | Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico. |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| AU2005268893B2 (en) * | 2004-08-05 | 2011-10-13 | F. Hoffmann-La Roche Ag | Indole, indazole or indoline derivatives |
| FR2889383A1 (fr) * | 2005-08-01 | 2007-02-02 | France Telecom | Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information |
| AR059733A1 (es) * | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| US20090176825A1 (en) | 2006-05-16 | 2009-07-09 | Fitch Duke M | Prolyl hydroxylase inhibitors |
| JO2934B1 (en) | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| PL3357911T3 (pl) * | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| US8048894B2 (en) | 2007-04-18 | 2011-11-01 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| EP2155746A2 (en) | 2007-05-04 | 2010-02-24 | Amgen, Inc | Diazaquinolones that inhibit prolyl hydroxylase activity |
| JP5408434B2 (ja) | 2007-07-03 | 2014-02-05 | アステラス製薬株式会社 | アミド化合物 |
| EA201000915A1 (ru) * | 2007-11-30 | 2011-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Ингибиторы пролилгидроксилазы |
| JP2011505367A (ja) * | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| US8324241B2 (en) * | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
| US20110039895A1 (en) * | 2008-04-30 | 2011-02-17 | Glaxo Smith Kline LLC., a corporation | Prolyl hydroxylase inhibitors |
| HRP20160488T1 (hr) | 2008-12-19 | 2016-06-17 | Leo Pharma A/S | Triazolopiridini kao inhibitori fosfodiesteraze za liječenje kožnih bolesti |
| EP3594213A1 (en) * | 2009-07-17 | 2020-01-15 | Japan Tobacco Inc. | Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers |
-
2010
- 2010-07-16 EP EP19188636.5A patent/EP3594213A1/en not_active Withdrawn
- 2010-07-16 BR BR112012001157A patent/BR112012001157A2/pt not_active Application Discontinuation
- 2010-07-16 EP EP10799914.6A patent/EP2455381B9/en active Active
- 2010-07-16 PT PT107999146T patent/PT2455381E/pt unknown
- 2010-07-16 KR KR1020177003353A patent/KR101850661B1/ko active Active
- 2010-07-16 TW TW099123410A patent/TWI485150B/zh active
- 2010-07-16 US US12/837,679 patent/US8283465B2/en active Active
- 2010-07-16 MX MX2012000766A patent/MX2012000766A/es active IP Right Grant
- 2010-07-16 ME MEP-2014-82A patent/ME01858B/me unknown
- 2010-07-16 RS RSP20140406 patent/RS53499B1/sr unknown
- 2010-07-16 HR HRP20140705AT patent/HRP20140705T1/hr unknown
- 2010-07-16 KR KR1020127004258A patent/KR101706803B1/ko active Active
- 2010-07-16 SI SI201030682T patent/SI2455381T1/sl unknown
- 2010-07-16 NZ NZ598242A patent/NZ598242A/xx unknown
- 2010-07-16 AR ARP100102614A patent/AR077417A1/es active IP Right Grant
- 2010-07-16 MY MYPI2012000223A patent/MY160814A/en unknown
- 2010-07-16 EP EP14160395.1A patent/EP2746282A1/en not_active Withdrawn
- 2010-07-16 RU RU2012105467/04A patent/RU2538963C2/ru active
- 2010-07-16 KR KR1020267000195A patent/KR20260012830A/ko active Pending
- 2010-07-16 DK DK10799914.6T patent/DK2455381T5/en active
- 2010-07-16 AU AU2010271732A patent/AU2010271732B2/en active Active
- 2010-07-16 WO PCT/JP2010/062037 patent/WO2011007856A1/ja not_active Ceased
- 2010-07-16 KR KR1020237040564A patent/KR20230165366A/ko not_active Ceased
- 2010-07-16 PL PL10799914T patent/PL2455381T3/pl unknown
- 2010-07-16 PE PE2012000056A patent/PE20120629A1/es active IP Right Grant
- 2010-07-16 ES ES10799914.6T patent/ES2477968T3/es active Active
- 2010-07-16 KR KR1020187010331A patent/KR20180042443A/ko not_active Ceased
- 2010-07-16 JP JP2010161144A patent/JP5021797B2/ja active Active
- 2010-07-16 SG SG2012003570A patent/SG178049A1/en unknown
- 2010-07-16 CN CN201080032238.2A patent/CN102471337B/zh active Active
- 2010-07-16 CA CA2768505A patent/CA2768505C/en active Active
-
2012
- 2012-01-15 IL IL217541A patent/IL217541A/en active IP Right Grant
- 2012-01-31 CO CO12014916A patent/CO6430426A2/es active IP Right Grant
- 2012-04-26 JP JP2012101381A patent/JP2012144571A/ja not_active Ceased
- 2012-09-06 US US13/605,329 patent/US20130096155A1/en not_active Abandoned
-
2014
- 2014-10-09 JP JP2014207896A patent/JP2015003933A/ja active Pending
-
2015
- 2015-05-22 SM SM201500122T patent/SMT201500122B/xx unknown
- 2015-06-25 US US14/749,966 patent/US20160145254A1/en not_active Abandoned
- 2015-12-08 JP JP2015239065A patent/JP2016040321A/ja active Pending
-
2017
- 2017-07-10 JP JP2017134270A patent/JP6434575B2/ja not_active Expired - Fee Related
-
2018
- 2018-11-08 JP JP2018210486A patent/JP2019019144A/ja active Pending
-
2020
- 2020-04-20 JP JP2020074508A patent/JP2020111612A/ja not_active Ceased
-
2022
- 2022-06-29 JP JP2022104161A patent/JP2022126843A/ja not_active Ceased
-
2024
- 2024-04-24 JP JP2024070200A patent/JP2024091878A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008006540A1 (en) | 2006-07-12 | 2008-01-17 | Syngenta Participations Ag | Triazolopyridine derivatives as herbicides |
| WO2009146358A1 (en) | 2008-05-29 | 2009-12-03 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine and related analogs as sirtuin modulators |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101850661B1 (ko) | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 | |
| CN109790148B (zh) | 具有usp30抑制剂活性的氰基取代的杂环 | |
| US20200017492A1 (en) | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent | |
| EP3741752A1 (en) | Tam family kinase /and csf1r kinase inhibitor and use thereof | |
| AU2006311729A1 (en) | Benzimidazole derivatives as gyrase inhibitors | |
| TW202444700A (zh) | 作為sarm1抑制劑之經取代1h-吡唑-4-甲醯胺化物 | |
| KR20210048589A (ko) | 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용 | |
| HK1168346B (en) | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer | |
| CN121591722A (zh) | 作为蛋白质酪氨酸磷酸酶抑制剂的含双键取代的化合物及其应用 | |
| HK40041650A (en) | Tam family kinase /and csf1r kinase inhibitor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| FPAY | Annual fee payment |
Payment date: 20210324 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20220302 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 9 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R14-asn-PN2301 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |